Biodesix, Inc. BDSX

Company Overview

Biodesix, Inc. is a U.S.-based diagnostics company focused on developing and commercializing blood-based diagnostic tests for lung disease, particularly lung cancer. The company operates within the precision medicine, molecular diagnostics, and biopharmaceutical services industries, using proteomics, genomics, and advanced laboratory analytics to support earlier disease detection, treatment selection, and therapy monitoring. Its primary revenue drivers include diagnostic testing services for healthcare providers and biopharmaceutical services provided to pharmaceutical and biotechnology companies engaged in oncology drug development.

The company’s core commercial offerings include the Nodify Lung testing portfolio for assessing pulmonary nodules and the IQlung testing portfolio for lung cancer treatment guidance. Biodesix also provides laboratory and data services through its biopharma partnerships, supporting clinical trials and biomarker research. The company was founded in 2005 and evolved from a proteomics-focused diagnostics platform into a broader precision diagnostics business centered on lung disease management and oncology applications. Its strategic positioning is tied to its integrated data analytics capabilities, CLIA-certified laboratory infrastructure, and relationships with pulmonologists, oncologists, and pharmaceutical developers.